ReviewKorean journal of anesthesiology2026
Amino acids for renal protection: time to implement in clinical practice.
Review in Korean journal of anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common complication observed in both surgical and critical care settings. The PROTECTION trial, published in the New England Journal of Medicine, showed that short-term low-dose infusions of amino acids (AA) reduced the rate of both any-stage and severe AKI in more than 3,500 cardiac surgery patients. Its publication resulted in the inclusion of AA in the European guidelines for the management of adult cardiac surgery with cardiopulmonary bypass and changes in clinical practice worldwide. This rapid dissemination has raised practical questions regarding patient selection, formulation choice, dosages, and duration of infusion. In this narrative review, we used the "Wh-questions" framework to provide a clear and structured overview on perioperative AA administration. We outline the historical background of AA-mediated renal protection, the pathophysiological context, and the available AA formulations most commonly used in clinical studies. In addition to the conclusive evidence in cardiac surgery, data supporting potential benefits in other high-risk populations, including urological surgery patients and those receiving temporary mechanical circulatory support, are growing. Importantly, recent insights suggest that clinicians must not exceed a 48-hour infusion. Finally, a reduction in hospitalization costs associated with AA infusions has been demonstrated by a recent health economic analysis. Overall, AA infusions represent a simple, safe, and inexpensive intervention that is effective at reducing AKI. These data further support their immediate adoption in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.